Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AstraZeneca Submits EUA for LAAB Combo for COVID Prevention | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

AstraZeneca Submits EUA for LAAB Combo for COVID Prevention

Results from the PROVENT pre-exposure prophylaxis trial showed AZD7442 reduced the risk of developing symptomatic COVID-19 by 77%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AstraZeneca has submitted a request to the U.S. FDA for an Emergency Use Authorization for AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic COVID-19.
 
If granted, AZD7442 would be the first LAAB to receive an EUA for COVID-19 prevention. It is the first LAAB with Phase III data demonstrating a statistically significant reduction in the risk of developing symptomatic COVID-19 compared to placebo.
 
Results from the PROVENT pre-exposure prophylaxis trial showed AZD7442 reduced the risk of developing symptomatic COVID-19 by 77% compared to placebo. Importantly, the trial population included people with co-morbidities and who may be in need of additional protection from SARS-CoV-2 infection. Greater than 75% of participants in PROVENT presented with co-morbidities associated with an increased risk of severe disease or a reduced immune response to vaccination. The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis. AZD7442 was well-tolerated.
 
The EUA request filing includes safety and efficacy data from the PROVENT and STORM CHASER Phase III trials and the Phase I trial.
 
AZD7442 was optimized using AstraZeneca’s YTE half-life extension technology, which more than triples the durability of its action compared to conventional antibodies.
 
Preliminary ‘in vitro’ findings demonstrate that AZD7442 demonstrates broad anti-COVID activity, and in particular neutralizes recent emergent SARS-CoV-2 viral variants, including the Delta and Mu variants.
 
Discussions regarding supply agreements for AZD7442 are ongoing with the U.S. Government as well as other governments around the world.
 
AZD7442 is a combination of two LAABs – tixagevimab (AZD8895) and cilgavimab (AZD1061) – derived from B-cells donated by convalescent patients after SARS-CoV-2 virus. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein and were optimized by AstraZeneca with half-life extension and reduced Fc receptor and complement C1q binding.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics